Biomx Inc (NYSE MKT:PHGE) — Market Cap & Net Worth
Market Cap & Net Worth: Biomx Inc (PHGE)
Biomx Inc (NYSE MKT:PHGE) has a market capitalization of $911.25K ($911.25K) as of May 22, 2026. Listed on the NYSE MKT stock exchange, this USA-based company holds position #30468 globally and #6020 in its home market, demonstrating a -7.16% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biomx Inc's stock price $0.60 by its total outstanding shares 1526640 (1.53 Million). Analyse PHGE cash flow conversion to see how efficiently the company converts income to cash.
Biomx Inc Market Cap History: 2019 to 2026
Biomx Inc's market capitalization history from 2019 to 2026. Data shows change from $147.86 Million to $911.25K (-50.69% CAGR).
Biomx Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Biomx Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
-11.97x
Biomx Inc's market cap is -11.97 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $2.85 Million | $-134.00K | -$28.32 Million | -21.30x | N/A |
| 2023 | $4.27 Million | $-357.00K | -$26.17 Million | -11.97x | N/A |
Competitor Companies of PHGE by Market Capitalization
Companies near Biomx Inc in the global market cap rankings as of May 22, 2026.
Key companies related to Biomx Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #224 globally with a market cap of $109.25 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #410 globally with a market cap of $66.94 Billion USD.
- argenx NV ADR (NASDAQ:ARGX): Ranked #573 globally with a market cap of $45.97 Billion USD.
- UCB S.A. UNSP.ADR 1/2 (F:UNC0): Ranked #593 globally with a market cap of $44.84 Billion USD ( €38.35 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #224 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $109.25 Billion | $430.44 |
| #410 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $66.94 Billion | $649.76 |
| #573 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
| #593 | UCB S.A. UNSP.ADR 1/2 | F:UNC0 | $44.84 Billion | €120.00 |
Biomx Inc Historical Marketcap From 2019 to 2026
Between 2019 and today, Biomx Inc's market cap moved from $147.86 Million to $ 911.25K, with a yearly change of -50.69%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $911.25K | -68.08% |
| 2025 | $2.85 Million | +156.13% |
| 2024 | $1.11 Million | -73.92% |
| 2023 | $4.27 Million | +49.73% |
| 2022 | $2.85 Million | -88.31% |
| 2021 | $24.43 Million | -74.92% |
| 2020 | $97.40 Million | -34.12% |
| 2019 | $147.86 Million | -- |
End of Day Market Cap According to Different Sources
On May 21st, 2026 the market cap of Biomx Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $911.25K USD |
| MoneyControl | $911.25K USD |
| MarketWatch | $911.25K USD |
| marketcap.company | $911.25K USD |
| Reuters | $911.25K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Biomx Inc
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. It also developing BX004, a phage therapy for cystic f… Read more